Bird Flu :: UN says $ 1.3 billion more needed to fight bird flu
As much as $1.3 billion more is needed to fight bird flu, with more than $500 million of that going to Africa, World Bank and U.N. experts said.
As much as $1.3 billion more is needed to fight bird flu, with more than $500 million of that going to Africa, World Bank and U.N. experts said.
South Korea slaughtered hundreds of dogs and pigs in efforts to stem the spread of the deadly H5N1 strain of bird flu.
Novartis unveiled today new data on its promising pipeline amid plans for multiple new product approvals and launches over the next two years. Many of these anticipated approvals are for potentially best-in-class medicines that would advance treatment standards for patients with hypertension, diabetes, cancer and other diseases.
BioCryst’s Peramivir is a new flu drug that can kill deadly strains of bird flu, and this antiviral drug is promising to transform global preparations for an influenza pandemic.
North Korea is stepping up measures to prevent bird flu, its official media said today. North Korea will take all precautions to prevent the spread of an outbreak of the highly virulent H5N1 strain in South Korea.
South Korean quarantine officials are scrambling to control an outbreak of the virulent H5N1 strain of bird flu in one of the Korea?s biggest poultry producing areas, cordoning off infected farms and slaughtering thousands of birds, and disinfecting the area.
The Nha Trang Institute of Vaccines and Biological Products, Vietnam has announced that it has successfully produced 5,000 doses of a H5N1 vaccine for humans from chicken embryos, which is currently being validated by the Ministry of Health before possible human trials.
South Korea’s farm ministry said on Thursday it had discovered a suspected case of bird flu at a poultry farm in the southwest of the country, which could be the country’s first outbreak in about three years.
GlaxoSmithKline (NYSE:GSK), one of the world?s largest vaccine manufacturers, today announced it has been awarded a contract to supply pre-pandemic vaccines to the US strategic national stockpile. The company has received an initial $40 million order under the contract from the U.S. Department of Health and Human Services (HHS) for bulk H5N1 antigen – the substance in the vaccines that will help produce an immune response.
Novartis announced today that it has been awarded a contract valued at USD 40.95 million to supply to the US government a pre-pandemic influenza vaccine* against the H5N1 avian influenza strain. Global health authorities have identified H5N1 as an influenza strain with pandemic potential.